Risk for Lung Cancer, Asthma, and COPD; Integrating Clinical and Airway Biomarker

肺癌、哮喘和慢性阻塞性肺病的风险；

• 批准号: 8109307
• 负责人: SIMON D SPIVACK
• 金额: $ 16.77万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-12 至 2015-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8109307
• 关键词: Address; Area; Arts; Asthma; Award; Biological Markers; Cancer Detection; Chronic Obstructive Airway Disease; Clinical; Clinical Research; Clinical Trials Design; Collaborations; Data; Data Analyses; Data Set; Development; Dimensions; Disease; Drug Formulations; Early Diagnosis; Epidemiology; Future; Genetic; Goals; Hispanics; Individual; Investments; Joints; Laboratories; Link; Lung; Lung diseases; Malignant neoplasm of lung; Medical Oncology; Medicine; Mentors; Mentorship; Methodology; Mid-Career Clinical Scientist Award (K24); Molecular; Molecular Biology; Monitor; Nursing Faculty; Population; Postdoctoral Fellow; Prevention; Prevention strategy; Public Health; Public Health Schools; Pulmonology; Research; Research Personnel; Research Project Grants; Risk; Risk Assessment; Role; Rotation; Sampling; Series; Techniques; Time; Tissues; Touch sensation; Training; Translational Research; Universities; base; career; case control; cohort; college; community health study; design; disorder risk; experience; human study; interest; member; next generation; novel; oncology; patient oriented research; population based; prospective; statistics; tool; translational study

DESCRIPTION (provided by applicant): The overall goal of this K24 award proposal is to further the development of Dr. Spivack into an exceptional trans-disciplinary patient-oriented research mentor, capable of guiding trainees from developing a clinical hypothesis to formulation of a series of answerable component questions. Key components of that mentorship role will include the articulation of critical aspects of relevant human study design; invoking, where applicable, the creative procurement and analyses of relevant tissue biomarkers by collaboration with appropriate laboratory support; and engagement of sophisticated data analytic techniques to definitively address the hypotheses in a clinically-meaningful manner. The overall aim of the proposal is therefore to support this translational mentorship function. The Specific Aims are: 1) Provide protected time for the PI to further train in epidemiology and statistics, particularly with respect to accrual and analysis of multi-dimensional observational datasets, both case-control/cross-sectional, and prospective cohorts with a time dimension. This will include those studies invoking genetic data analyses, and in prevention trials design and analyses. 2) Provide clinical-translational mentorship for one to two junior clinical faculty members, and a continuous rotation of two to four Pulmonary Medicine or Medical Oncology post-doctoral clinical fellows, at any given time over the project period. 3) Initiate the assessment of prospective cohort-based clinical risk, invoking clinical and airway-specific molecular biomarker analyses of common lung diseases (lung cancer, asthma, COPD), for facilitating the development of early detection and prevention strategies. The current capacity of the Spivack laboratory to develop, sample, accrue and analyze a population, and to conceive, develop and apply state-of-art molecular methodologies for airway disease biomarker analyses to the same population, provides a very unique training opportunity for clinical and other post-doctoral trainees in Medicine, Pulmonary Medicine, Oncology, and in translational research in general. Facilitated by a K24 award, the mentoring experience will be markedly enhanced, as will a shift to evaluating existing prospective cohorts, in a trans-disciplinary manner. The research questions are fundamentally clinical: (1) Can we identify individuals at risk for lung cancer, asthma, and COPD, to facilitate early detection strategies? (2) Can we intervene in individuals, to reduce that risk, using preventive strategies?

描述（由申请人提供）：这项K24奖励提案的总体目标是将Spivack博士进一步发展成一个卓越的跨学科的以患者为导向的研究导师，能够指导受训者开发临床假设，以制定一系列可回答的组件问题。该指导角色的关键组成部分将包括对相关人类研究设计的关键方面的表达；在适用的情况下，通过合作的实验室支持来调用相关组织生物标志物的创造性采购和分析；以及复杂数据分析技术的参与，以临床上的方式确定地解决这些假设。因此，该提案的总体目的是支持这种翻译指导职能。具体目的是： 1）为PI提供了受保护的时间，以进一步训练流行病学和统计数据，尤其是在应计和分析多维观察数据集的情况下，包括病例对照/横截面以及具有时间维度的前瞻性同类群。这将包括那些调用遗传数据分析的研究以及预防试验设计和分析。 2）在项目期间的任何给定时间，为一到两个初级临床教职员工提供临床翻译指导，并连续旋转两到四种肺部医学或医学肿瘤学后临床研究员。 3）启动基于前瞻性队列的临床风险评估，援引常见肺部疾病（肺癌，哮喘，COPD）的临床和气道特异性分子生物标志物分析，以促进早期发现和预防策略的发展。 Spivack实验室的当前能力开发，采样，积累和分析人群，并构想，开发和应用最先进的分子方法论，以对同一人群进行气道疾病生物标记分析，为临床和其他多功能的培训机会提供了非常独特的培训机会，并在医学，肺部医学，肿瘤学中以及翻译方面的医学，肺部医学，一般性研究。由K24奖的促进，指导经验将得到明显提高，以跨学科的方式评估现有的潜在人群。研究问题从根本上是临床上的：（1）我们是否可以识别出患有肺癌，哮喘和COPD风险的人，以促进早期检测策略？ （2）我们可以使用预防策略干预个人，以降低这种风险？